Article

ASCO Updates Clinical Guidelines for HER2-Negative Breast Cancer

The guidelines suggest various treatment options available, following consideration of the patient's status and preference.

Methods A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1993 through to current was completed. Outcomes of interest included survival, progression-free survival, response, quality of life, and adverse effects. Guideline recommendations were evidence based and were agreed on by the Expert Panel via consensus.

Results Seventy-nine studies met the inclusion criteria, comprising 20 systematic reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and subsequent treatment. These trials form the evidence base for the guideline recommendations.

Link to the article: http://bit.ly/1qo60AD

Source: Journal of Clinical Oncology

To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)— negative (or unknown) advanced breast cancer.

Related Videos
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Neal D. Shore, MD
Amit Singal, MD, UT Southwestern Medical Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo